Interoception mediates the association between social support and sociability in patients with major depressive disorder

BACKGROUND Interoception dysfunction has an important impact on the onset and development of major depressive disorder(MDD).Social support serves as a protective factor against MDD,and sociability also plays a significant role in this condition.These interconnected constructs-social support and sociability-play pivotal roles in MDD.However,no research on the mechanisms underlying the associations be-tween social support and sociability,particularly the potential role of interocep-tion,have been reported.ception,social support,and sociability,respectively.A mediation analysis model for the eight dimensions of intero-ception(noticing,not distracting,not worrying,attention regulation,emotional awareness,self-regulation,body listening,and trust),social support,and sociability were established to evaluate the mediating effects.RESULTS A partial correlation analysis of eight dimensions of the MAIA-2,SSRS,and TSBI scores,with demographic data as control variables,revealed pairwise correlations between the SSRS score and both the MAIA-2 score and TSBI score.In the major depression(MD)group,the SSRS score had a positive direct effect on the TSBI score,while the scores for body listening,emotional awareness,self-regulation,and trust in the MAIA-2C had indirect effects on the TSBI score.In the HC group,the SSRS score had a positive direct effect on the TSBI score,and the scores for attention regulation,emotional awareness,self-regulation,and trust in the MAIA-2C had indirect effects on the TSBI score.The proportion of mediators in the MD group was lower than that in the HC group.CONCLUSION Interoceptive awareness is a mediating factor in the association between social support and sociability in both HCs and depressed patients.Training in interoceptive awareness might not only help improve emotional regulation in depressed patients but also enhance their social skills and support networks.

Saffron (Crocus sativus L.) and major depressive disorder:a meta-analysis of randomized clinical trials

Due to safety concerns and side effects of many antidepressant medications, herbal psychopharmacology research has increased, and herbal remedies are becoming increasingly popular as alternatives to prescribed medications for the treatment of major depressive disorder （MDD）. Of these, accumulating trials reveal positive effects of the spice saffron （Crocus sativus L.） for the treatment of depression. A comprehensive and statistical review of the clinical trials examining the effects of saffron for treatment of MDD is warranted. OBJECTIVE： The purpose of this study was to conduct a meta-analysis of published randomized controlled trials examining the effects of saffron supplementation on symptoms of depression among participants with MDD. SEARCH STRATEGY： We conducted electronic and non-electronic searches to identify all relevant randomized, double-blind controlled trials. Reference lists of all retrieved articles were searched for relevant studies. INCLUSION CRITERIA： The criteria for study selection included the following： （1） adults （aged 18 and older） with symptoms of depression, （2） randomized controlled trial, （3） effects of saffron supplementation on depressive symptoms examined, and （4） study had either a placebo control or antidepressant comparison group. DATA EXTRACTION AND ANALYSIS： Using random effects modeling procedures, we calculated weighted mean effect sizes separately for the saffron supplementation vs placebo control groups, and for the saffron supplementation vs antidepressant groups. The methodological quality of all studies was assessed using the Jadad score. The computer software Comprehensive Meta- analysis 2 was used to analyze the data. RESULTS： Based on our pre-specified criteria, five randomized controlled trials （n = 2 placebo controlled trials, n = 3 antidepressant controlled trials） were included in our review. A large effect size was found for saffron supplementation vs placebo control in treating depressive symptoms （M ES = 1.62, P 〈 0.001）, revealing that saffron supplementation significantly reduced depression symptoms compared to the placebo control. A null effect size was evidenced between saffron supplementation and the antidepressant groups （M ES = -0.15） indicating that both treatments were similarly effective in reducing depression symptoms. The mean Jadad score was 5 indicating high quality of trials. CONCLUSION： Findings from clinical trials conducted to date indicate that saffron supplementation can improve symptoms of depression in adults with MDD. Larger clinical trials, conducted by research teams outside of Iran, with long-term follow-ups are needed before firm conclusions can be made regarding saffron＇s efficacy and safety for treating depressive symptoms.

Profiles of depressive disorders and influencing factors among the elderly in China: protocol for a secondary data analysis

Background:Depressive disorders have become a major risk factor that influences people’s health worldwide,but few studies have focused on the prevalence of depressive disorders among the Chinese elderly and their characteristics of depressive disorders.The current study is a secondary data analysis designed to explore the profiles of depressive disorders in the Chinese elderly by latent profile analysis.Methods:The China Health and Retirement Longitudinal Study(CHARLS 2018)database will be used for analysis.Latent profile analysis will be employed to identify the profiles of depressive disorders using data from the subsection“CESD Depression”in the section“Cognition and Depression”.Stepwise multinomial logistic regression will be used to explore the influencing factors of different profiles of depressive disorders among the Chinese elderly.Discussion:The prevalence of depressive disorders among the Chinese elderly and their profiles of depressive disorders will be reported.Possible influencing factors may include some demographic characteristics and associated psychological elements,which will provide a reference for further research and precise intervention.

Evaluation Efficacy and Safety of Vortioxetine 20 mg/d versus Placebo for Treatment Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Major depressive disorder, a common debilitating illness, is one of the leading causes of disability and disease worldwide. Different drugs for the treatment of patients with major depression can be used. Vortioxetine for the treatment of major depressive disorder was approved by the Food and Drug Administration (FDA) in 2013. This study aimed to evaluation efficacy and safety Vortioxetine 20 mg/d compared placebo in major depressive disorder. To conduct this study, we searched Pub Med, Cochrane library, Scopus, and Central Register of Controlled Trials. This study by including randomized controlled trials (RCTs) that evaluated this study by including randomized controlled trials (RCTs) that evaluated Vortioxetine 20 mg/d in patients with major depressive disorder. Data analysis was conducted by standard mean different ratios (SMD) with 95% confidence intervals (CIs), P values and odds ratios (ORs) for adverse events with 95% confidence intervals (CIs) and P values;heterogeneity testing and sensitivity analysis was also performed in this study. We found that 4 articles met the inclusion criteria and were finally used for this meta-analysis. Results showed statistical significance in the MADRS (Montgomery-&Aringsberg Depression Rating Scale), SMD = -4.75 with 95% CI [-6.84, -2.65] and P value < 0.00001), for Clinical Global Impression Scale-Improvement (CGI-I) SMD was -4.34 with 95% CI [-6.41, -2.27] and P value < 0.00001, and for Sheehan Disability Scale (SDS) SMD was -2.62 with 95% CI [-3.99, -1.25] and P value < 0.00001. The pooled analysis for safety demonstrated for diarrhea OR = 0.92 with 95% CI [0.46, 1.83] , P value = 0.09, for dry mouth OR = 1.74 with 95% CI [1.07, 2.83] , P value = 0.80, for dizziness OR = 1.62 with 95% CI [0.72, 3.66] , P value = 0.05, for fatigue OR = 1.17 with 95% CI [0.34, 4.08], P value = 0.07, for headache OR = 1.28 with 95% CI [0.91, 1.79], P value = 0.60 and for nausea OR = 4.78 with 95% CI [3.43, 6.67], P value = 0.61. Vortioxetine 20 mg/d versus placebo showed a significant difference for nausea and dry mouth, but no significant differences were observed for the four adverse effects. In several studies of the drug Vortioxetine 20 mg/d, the treatment of major depressive illness has been more effective for evaluating the effectiveness of this drug, which must be more clinical studies of sound.

Efficacy and Safety of Vortioxetine and Duloxetine 60 mg Compared Placebo for the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis

Background: Major depressive disorder is a serious public health problem affecting the lives of millions in the worldwide and leading causes of disability and disease. This study aimed to evaluate the efficacy and safety of Vortioxetine and Duloxetine 60 mg compared to placebo for the treatment of major depressive disorder. Method: We searched the Cochrane library, Pub Med, CRD, Scopus, and Central Register of Controlled Trials to January 2015. We also searched ClinicalTrials.gov, International depressive disorder Conference and the Anxiety Disorders and Depression Conference. We identified that five randomized clinical trials were ultimately included in a Meta analysis. Data analysis was conducted by Standardized Mean Differences (SMD) for Montgomery-&Aring;sberg Depression Rating Scale (MADRS), and Odds Ratio (OR) for adverse events. The SMD and OR reported by 95% CI. Results: Results showed statistical significance in the MADRS for Vortioxetine (SMD = ﹣3.29;95% CI ﹣4.47 to ﹣2.10;I2 = 99.3%) and for Duloxetine 60 mg (SMD = ﹣6.35;95% CI ﹣8.84, ﹣3.87;I2 = 99.3%). Results showed that the Vortioxetine 2.5, 5, 10, 15, 20 mg and overall compared to placebo showed a significance for Nausea and no significance for diarrhea, dry mouth, dizziness, fatigue and headache. Also results of Duloxetine 60 mg showed a significant effect for dry mouth, dizziness, fatigue and nausea. Conclusion: It is necessary to do more studies so as to better assess and much more powerful than the evidence for the use of this drug in the treatment of depression.

Meta-analysis of brain activation in depressive patients with emotional perception disorders

OBJECTIVE：To elucidate the distribution of abnormally activated brain regions in depressive patients during emotional perception processing using activation likelihood estimation,a quantitative meta-analytic technique.DATA SOURCES：Computer-based online retrieval was conducted using the PscyINFO,Pubmed and CNKI databases,searching literature from the establishment of each database until June 2010.STUDY SELECTION：Inclusion criteria：（1） studies examined emotion perception tasks using func-tional magnetic resonance imaging; （2） studies indicated regional brain activation abnormalities in depressive patients compared with controls in standard Talairach or MNI coordinates.Any analyzed coordinates based on the MNI system were converted to Talairach space with icbm2tal software.The map of activation likelihood estimation was finally created through the Gaussian smooth （full-width half-maximum=8 mm）,permutation test and corrected for multiple comparisons using the false discovery rate method （q=0.05） with Ginger-ALE 2.0 software.MAIN OUTCOME MEASURES：Activation of brain regions in patients.RESULTS：Seventeen studies were identified,involving a total of 261 patients,273 healthy controls and 201 foci.Meta-analysis revealed a dysfunctional emotion regulation loop in depressive patients,comprised of the prefrontal cortex,the basal ganglia and the limbic lobe,in which the amygdala was a key component.During emotion processing,the left prefrontal cortex and basal ganglia were hy-poactive among depressive patients,whereas the opposite change was found in the limbic lobe.CONCLUSION：Abnormal connections among the prefrontal cortex,basal ganglia and limbic lobe may be involved in the pathophysiology of depressive disorder.

Aberrant Global and Regional Topological Organization of the Fractional Anisotropy-weighted Brain Structural Networks in Major Depressive Disorder

Background： Most previous neuroimaging studies have focused on the structural and functional abnormalities of local brain regions in major depressive disorder （MDD）. Moreover, the exactly topological organization of networks underlying MDD remains unclear. This study examined the aberrant global and regional topological patterns of the brain white matter networks in MDD patients. Methods： The diffusion tensor imaging data were obtained from 27 patients with MDD and 40 healthy controls. The brain fractional anisotropy-weighted structural networks were constructed, and the global network and regional nodal metrics of the networks were explored by the complex network theory. Results： Compared with the healthy controls, the brain structural network of MDD patients showed an intact small-world topology, but significantly abnormal global network topological organization and regional nodal characteristic of the network in MDD were found. Our findings also indicated that the brain structural networks in MDD patients become a less strongly integrated network with a reduced central role of some key brain regions. Conclusions： All these resulted in a less optimal topological organization of networks underlying MDD patients, including an impaired capability of local information processing, reduced centrality of some brain regions and limited capacity to integrate information across different regions. Thus, these global network and regional node-level aberrations might contribute to understanding the pathogenesis of MDD from the view of the brain network.

Antidepressants for bipolar disorder A meta-analysis of randomized, double-blind, controlled trials

OBJECTIVE： To examine the efficacy and safety of short-term and long-term use of antidepres- sants in the treatment of bipolar disorder. DATA SOURCES： A literature search of randomized, double-blind, controlled trials published until December 2012 was performed using the PubMed, ISI Web of Science, Medline and Cochrane Central Register of Controlled Trials databases. The keywords ＂bipolar disorder, bipolar I disorder, bipolar II disorder, bipolar mania, bipolar depression, cyclothymia, mixed mania and depression, rapid cycling and bipolar disorder＂, AND ＂antidepressant agent, antidepressive agents second- generation, antidepressive agents tricyclic, monoamine oxidase inhibitor, noradrenaline uptake in- hibitor, serotonin uptake inhibitor, and tricyclic antidepressant agent＂ were used. The studies that were listed in the reference list of the published papers but were not retrieved in the above-mentioned databases were supplemented. STUDY SELECTION： Studies selected were double-blind randomized controlled trials assessing the efficacy and safety of antidepressants in patients with bipolar disorder. All participants were aged 18 years or older, and were diagnosed as having primary bipolar disorder. Antidepressants or antidepressants combined with mood stabilizers were used in experimental interventions. Placebos, mood stabilizers, antipsychotics and other antide pressants were used in the control interventions. Studies that were quasi-randomized studies, or used antidepressants in combination with antipsy- chotics in the experimental group were excluded. All analyses were conducted using Review Man- ager 5.1 provided by the Cochrane Collaboration.

抽动障碍患儿共患ADHD的影响因素及中介效应分析

目的分析抽动障碍(tic disorders,TD)患儿共患注意缺陷与多动障碍(attention deficit hyperactivity disorder,ADHD)的影响因素及路径关系中的中介效应。方法调查收集363例TD患儿的临床资料及人口学和家庭环境信息,采用多因素Logistic回归分析、路径分析及中介效应分析相结合的方法进行研究。结果放纵型家庭教养方式(OR=2.59)、TD病情中重度(OR=25.92)、合并行为问题(OR=3.72)是TD患儿共患ADHD的危险因素。中介效应分析结果显示,TD病情严重程度在TD诊断类型和合并行为问题之间起部分中介作用,中介效应大小为14.34%;TD合并行为问题在TD病情严重程度和共患ADHD之间起部分中介作用,中介效应大小为6.49%;TD合并行为问题在家庭教养方式和共患ADHD之间起部分中介作用,中介效应大小为24.14%。结论TD患儿共患ADHD与家庭环境、临床因素关系密切,在TD诊疗过程中应充分考虑到疾病本身、共患病以及中介变量的影响。

癌症对中老年人主观幸福感的影响研究——社交活跃度和抑郁情绪的链式中介作用

目的:探讨癌症对中老年人主观幸福感的影响以及社交活跃度和抑郁情绪的链式中介作用。方法:使用2018年中国健康与养老追踪调查(CHARLS)数据,选取年龄≥45岁的中老年人作为研究对象,最终样本12644人。采用多重中介模型评估主观幸福感的影响机制。结果:调查对象主观幸福感均值为3.25,癌症对主观幸福感的直接负向效应显著(β=-0.675,P<0.001),社交活跃度和抑郁情绪显著影响主观幸福感(β=0.006,P<0.05;β=-0.046,P<0.001)。社交活跃度和抑郁情绪对主观幸福感的简单中介效应分别为0.004(95%CI:0.001~0.008)和-0.057(95%CI:-0.098~-0.016);链式中介效应为-0.013(95%CI:-0.018~-0.007)。结论:社交活跃度和抑郁情绪在癌症对主观幸福感间存在链式中介效应,积极的社会参与能预防抑郁。加强癌症人群的心理干预,完善癌症患者社会参与机制,降低与时代的疏离感与陌生感,能提升其幸福感。

混合性焦虑抑郁障碍服务质量情感主题识别研究

[目的/意义]为识别在线医疗社区中混合性焦虑抑郁障碍患者评论医疗服务质量情感及主题,提出一种基于CNN-BiLSTM和LDA模型的服务质量情感主题识别模型。[方法/过程]首先,构建CNN-BiLSTM模型提取患者评论内外关键特征得到情感倾向分布;其次,运用LDA主题模型提取患者正负向评论主题,结合《医院评价标准(征求意见稿)》得到医疗服务质量主题,从分布和情感词对正负向服务质量进行挖掘。[结果/结论]CNN-BiLSTM的F1值为94.43%,均优于其他对比模型;结合LDA主题模型和相关文献得到5维医疗服务质量主题及分布;根据主题情感词及分布得到负向评论产生的主要原因,为识别和改善医疗服务质量提供有效决策支持。

接纳承诺疗法对抑郁障碍效果的meta分析

目的:评估接纳承诺疗法(ACT)对抑郁障碍患者的干预效果。方法:使用计算机检索Web of Science Core Collection、Pubmed、EMBASE、Cochrane Library、PsycINFO、中国知网、万方及维普全文数据库(截止到2023年10月23日),搜集接纳承诺疗法治疗抑郁障碍患者的随机对照研究(RCT)。使用STATA 17软件对符合纳入标准的文献数据进行meta分析。结果:共纳入11个RCT,随机效应模型分析结果表明,ACT能够有效降低抑郁水平(SMD=-1.22,95%CI:-2.05~-0.40,P<0.01),且具有一定维持效果(SMD=3.59,95%CI:1.57~5.62,P<0.01)。结论:接纳承诺疗法可以改善患者的抑郁。

自尊在孕妇产前抑郁与妊娠期疲劳间的中介作用

目的探讨自尊在孕妇产前抑郁与妊娠期疲劳间的中介作用,为制定针对性干预措施提供参考。方法采用一般资料调查表、爱丁堡产后抑郁量表、自尊量表、疲劳自评量表对401名门诊产检的孕妇进行调查。结果孕妇产前抑郁、自尊与疲劳得分分别为10.00(7.00,13.00)分、(32.28±4.00)分和8.93(3.57,25.00)分。妊娠期疲劳与产前抑郁呈正相关,与自尊呈负相关,产前抑郁与自尊负相关(均P<0.05);自尊在产前抑郁与妊娠期疲劳间的中介效应为0.076,占总效应的18.67%。结论孕妇中轻度疲劳发生率较高,自尊在抑郁与妊娠期疲劳间起部分中介作用;可通过提升孕妇自尊水平及缓解产前抑郁症状,从而改善疲劳。

护士产后返岗初期工作压力的潜在剖面及影响因素研究

目的探讨临床护士产后返岗初期工作压力的潜在剖面,并探究不同潜在类型影响因素,为制定产后返岗护士工作压力精准干预措施提供参考。方法采用便利抽样法,选取江苏省14所三级医院的200名产后返岗初期护士,应用护士产后返岗工作压力量表、匹兹堡睡眠指数量表、抑郁-焦虑-应激量表进行问卷调查,对护士产后返岗初期工作压力特征进行潜在剖面分析,分析产后返岗初期工作压力潜在类别的影响因素。结果护士产后返岗初期工作压力特征分为3个潜在类别:低压力组(26.0%)、中压力组(50.0%)、高压力组(24.0%)。回归分析结果显示,年龄、照顾孩子日均时长、返岗时调岗、睡眠质量及抑郁症状是产后返岗初期工作压力不同潜在类别的影响因素(均P<0.05)。结论护士产后返岗初期工作压力存在潜在异质性。护理管理者可根据不同潜在类别和影响因素,实施精准干预,帮助产后护士返岗后有效应对护理工作压力。

益肾调气法治疗肾虚肝郁型抑郁障碍远期复发率的多中心前瞻性队列研究

目的:评价益肾调气法对肾虚肝郁型抑郁障碍2年复发率的影响。方法:选取2017年1月至2018年4月在全国13个分中心招募肾虚肝郁型抑郁障碍患者,按照接受的治疗方案自然形成中医组、中西医组和西医组,比较3组的复发率。并根据干预的时间,将中医组和中西医组分为低、中、高3个暴露水平,比较不同水平的复发率,评价益肾调气法降低肾虚肝郁型抑郁障碍的远期复发率的效果。结果:共纳入肾虚肝郁型抑郁障碍1314例,其中中医组385例,西医组453例,中西医组476例。中医组、西医组、中西医组的两年复发率分别是23.61%,34.97%、18.14%。中医组比西医组使复发风险降低29.2%(P<0.05),中西医组比西医组使复发风险降低45.5%(P<0.001)。中医组以低中药水平暴露时间(TCM-ET)为参照,高TCM-ET较于低TCM-ET复发风险降低81.4%(P<0.01);中西医组以低TCM-ET为参照,中TCM-ET比低TCM-ET复发风险降低46.9%(P<0.05),高TCM-ET比低TCM-ET复发风险降低65.3%(P<0.01)。结论:益肾调气法治疗肾虚肝郁型抑郁障碍能够降低远期复发率,且中医药干预的暴露水平与复发率之间具有密切的关系,较长的暴露水平显著降低了患者的复发率。

广泛性焦虑障碍患者的灾难化信念、绝对化信念及症状的关系探讨

目的:探讨广泛性焦虑障碍患者的灾难化信念、绝对化信念、无法忍受不确定性、应对方式和焦虑症状之间的相互关系。方法:采用汉密尔顿焦虑量表、灾难化信念量表、绝对化信念量表、无法忍受不确定性量表和简易应对方式问卷,对2022年3月至12月就诊于南京脑科医院医学心理科门诊的177例广泛性焦虑障碍患者进行调查,构建心理网络模型,进一步进行中介分析。结果:指向自我的绝对化在网络中的中心性最强(预期影响=1.72),其次是对他人评价的灾难化(预期影响=1.02),二者在认知层面联系最紧密(权重=0.26)。无法忍受不确定性在灾难化信念与焦虑症状中起部分中介作用,中介效应占总效应的45.80%。结论:指向自我的绝对化和对他人评价的灾难化在网络中具有核心特征,灾难化信念通过无法忍受不确定性影响个体的焦虑症状。

数字健康技术对临床护士负性情绪和离职意愿干预效果的Meta分析

目的评价数字健康技术对临床护士负性情绪和离职意愿的干预效果。方法检索PubMed、Web of Science、Cochrane Library、中国知网、万方数据、维普网等数据库中,数字健康技术对临床护士负性情绪干预的随机对照试验,检索时限为建库至2023年10月,采用RevMan5.3软件进行Meta分析。结果共纳入17篇文献、2285名护士。Meta分析结果显示,与对照组比较,数字健康技术干预可显著减轻临床护士抑郁、焦虑情绪,改善睡眠质量,降低压力水平和离职意愿(均P<0.05);对创伤后应激障碍干预效果不明显。结论当前证据显示,数字健康技术干预对临床护士负性情绪和离职意愿有积极作用,但对其创伤后应激障碍的干预效果有待进一步验证。

帕罗西汀联合奥氮平对我国抑郁症合并睡眠障碍患者临床疗效的Meta分析

目的 系统评价帕罗西汀联合奥氮平与单用帕罗西汀对我国抑郁症合并睡眠障碍患者临床疗效的影响。方法 计算机检索PubMed、Embase、Cochrane Library、CINAHL、SinoMed、CNKI、VIP、WanFang Data数据库、SUMsearch和Google搜索引擎,搜集关于帕罗西汀联合奥氮平对比单用帕罗西汀治疗我国抑郁症合并睡眠障碍患者的随机对照试验(RCT),检索时限均从建库至2023年4月3日。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.3软件进行Meta分析。结果共纳入70个RCT,包含5 683例患者。Meta分析结果显示,(1)试验组患者的总有效率显著高于对照组[OR=5.98,95%CI(4.51,7.94),P <0.001];(2)试验组患者的匹兹堡睡眠质量指数评分在治疗后1个月[MD=-2.81,95%CI(-3.24,-2.38),P <0.001]、2个月[MD=-2.41,95%CI(-3.13,-1.70),P <0.001]、3个月[MD=-2.80,95%CI(-3.18,-2.42),P <0.001]和6个月[MD=-1.65,95%CI(-1.83,-1.48),P <0.001]均显著低于对照组;(3)试验组患者的汉密尔顿抑郁量表评分在治疗后1个月[MD=-5.79,95%CI(-6.63,-4.95),P <0.001]、2个月[MD=-4.33,95%CI(-5.45,-3.21),P <0.001]、3个月[MD=-3.76,95%CI(-4.17,-3.34),P <0.001]和6个月[MD=-3.38,95%CI(-3.60,-3.15),P <0.001]均显著低于对照组;(4)试验组患者的汉密尔顿焦虑量表评分显著低于对照组[MD=-3.47,95%CI(-3.78,-3.16),P <0.001]。结论 当前证据显示,与单用帕罗西汀相比,帕罗西汀联合奥氮平能提高我国抑郁症合并睡眠障碍患者临床治疗的总有效率,改善治疗后1个月、2个月、3个月、6个月的睡眠质量和抑郁症状,且降低焦虑情绪。受纳入研究数量和质量限制,上述结论尚需更多高质量研究予以验证。

基于情感词典的情感分析在抑郁中的研究进展(综述)

抑郁是常见的精神障碍之一,早期的识别与筛查是诊断和管理的前提与基础,基于情感词典的情感分析方法通过获取用户在社交媒体中发布的文本构建词典,利用程序语言构建模型,以分析用户的态度、情绪。本文对基于情感词典的情感分析的概况和实施方法进行介绍,分析其在抑郁领域的应用及发展前景,旨在为利用互联网早期识别与筛查抑郁个体提供参考,实现心理健康状态智能监测服务。

正念认知疗法对抑郁症患者干预疗效的Meta分析

目的回顾分析正念认知疗法(MBCT)对抑郁症患者正念水平、反刍思维、自杀意念、睡眠与生活质量、自我同情水平的干预疗效。方法提取万方数据、知网、中国生物医学文献数据库(CBM)、Embase、PubMed、the cochrane library建库至2022年3月31日公开发表的相关MBCT对抑郁症患者干预的随机对照实验文献,通过RevMan5.4软件分析。结果共纳入18篇文献1892例研究对象。本次meta分析的结果显示,观察组采用MBCT可以有效减轻抑郁症患者的躯体症状、优化患者的正念水平、降低反刍思维与自杀意念、调整睡眠与生活质量,疗效明显优于对照组。结论抑郁症患者采用MBCT干预疗效明显,适用于临床使用。